Overall rank by patents
#31,503
Across all tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 6 technology areas, active 2018–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
EMBR holds 8 US patents across 6 technology areas, rank #31,503 of 50,000 tracked assignees.
EMBR Labs Inc. has been granted 8 US utility patents between 2018 and 2023, placing EMBR Labs Inc. at rank #31,503 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.3 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, EMBR Labs Inc. is one of the more focused assignees in the PatentsView dataset. By volume, EMBR sits between Elitechgroup, Inc. (8 patents, rank #31,499) and Emteq Limited (8 patents, rank #31,507) - the closest US assignees by grant volume. The composite Innovation Score of 39.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 4 in the 2015–2019 window, a +0% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. EMBR Labs Inc.'s 23.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark EMBR Labs Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ELITECHGROUP, INC.
8 patents
ELITEGROUP COMPUTER SYSTEMS CO., LTD.
8 patents
ELLUMEN, INC.
8 patents
ELMINDA LTD.
8 patents
EMC SatCom Technologies LLC
8 patents
EMED Technologies Corporation
8 patents
EMPIRIX INC.
8 patents
EMTEQ LIMITED
8 patents
EMBR Labs Inc.
8 patents
What this shows EMBR holds 8 patents at rank #31,503, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #31,503 in granted patent volume.
Other assignees with the most granted patents in EMBR's primary technology class.
EMBR's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
39 Top 39% higher than 61% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 12.5% |
| 2019 | 3 | 37.5% |
| 2022 | 2 | 25.0% |
| 2023 | 2 | 25.0% |
Top 6 of 6 technology areas
Overall rank by patents
#31,503
Across all tracked assignees
39.1 out of 100
How to use this portfolio
EMBR's 8 grants land it in the top 39% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.